September 15th 2025, 7:00pm
Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.
September 15th 2025, 5:00pm
Walking the woods shows me how to release fear, grief, and expectations, trusting that letting go nourishes growth, resilience and life’s next season.
September 15th 2025, 4:00pm
For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as one expert explained.
September 15th 2025, 3:00pm
The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.
September 15th 2025, 1:00pm
Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.
September 14th 2025, 6:00pm
The changing seasons offer a profound metaphor for the circle of life, an idea that resonates deeply with me.
September 14th 2025, 2:00pm
Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.
September 13th 2025, 6:00pm
For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.
September 13th 2025, 2:00pm
As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.
September 12th 2025, 9:00pm
Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.
Top Breast Cancer Stories from October 2025
New Book Spotlights Cancer in Early Adulthood
Top Gastrointestinal Cancer News: October 2025
Hairy Cell Leukemia Experts Impart Advice on Care and Support